(Q36971140)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Xuemin Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Xiugen Zhang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Francis Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Paul Spearman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

25 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

8036-8048

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17936444%20AND%20SRC:MED&resulttype=core&format=json

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

MHC-I-restricted presentation of HIV-1 virion antigens without viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016

Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.016